Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. - Wikidata - awgldk - TriplyDB

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.

http://www.wikidata.org/entity/Q38825497

about

Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson’s Disease Relative to Alzheimer’s Disease and Controls.Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls.Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications.Orexin and Alzheimer's Disease.Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.

P2860

Q36284128-8A920926-67C6-43B2-A9F3-30E4425F28F7 Q39178864-4137B221-B2BB-4D1B-A1C7-D79703ACD6C9 Q39466212-DD756456-8E3C-428A-AD01-AC94C2421B6E Q45934067-E33CF417-55EC-452F-A893-D4ED170861E2 Q47124745-65E91657-A40F-42D7-9ED9-C0DA6BED05EF Q47194996-47028F67-31E2-4A4F-A914-392A9C707716 Q47221798-7ABBA466-8B99-4EE3-BC1D-7D5645B6B58C Q47763379-392A198C-7452-466D-89C3-461B13F4D655 Q47780791-C34F5F94-E6F2-4FCD-92C0-63639A6E6B93 Q50230072-A5D4EBD2-178A-400B-9700-DD256379B54E Q54118411-6623561C-5995-4366-91E2-3FD88F6A0507

P2860

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.

http://www.wikidata.org/entity/Q38825497

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cerebrospinal fluid biomarkers ...... ysiology to clinical practice.

@en

type

label

Cerebrospinal fluid biomarkers ...... ysiology to clinical practice.

@en

prefLabel

Cerebrospinal fluid biomarkers ...... ysiology to clinical practice.

@en

P1433

Q38825497-1C043524-D3B1-4B5E-B369-ED5903E8427C

P1476

Q38825497-93B52BA1-F853-4A62-AED1-41B37A324029

P2093

Q38825497-0A946A56-C63A-4691-92F4-38C8ED9C3437

Q38825497-639AC47D-838B-4B54-809B-BE4E2D7188A4

Q38825497-80FA7BF7-BDFC-4A4A-883A-117907198C60

P2860

Q38825497-014A74AC-FAEC-460A-B884-DFFE2F61A159

Q38825497-019E6683-9783-438D-BA76-2A0B6755CE55

Q38825497-03BA9721-0AE3-4619-9025-31FC4F4F7743

Q38825497-04574CE9-8456-4CEF-A8A3-D269B9884F03

Q38825497-06CC8EFC-AD85-4681-BF55-305B42F12FEC

Q38825497-07FA028C-C8C1-4010-8978-93F581091540

Q38825497-08CA9694-A1CB-4BA0-A100-14403B64731B

Q38825497-0AC181D6-4256-4A65-A7E0-9EB1D92BA994

Q38825497-0AE7A314-F02E-4E40-BC19-5F9F8CA9F267

Q38825497-0B484DCF-078B-47CD-90C6-2FEA0725F272

P304

Q38825497-6CD3CB07-710A-4CCB-B5BF-9EA6A435BCAC

P31

Q38825497-05d8df01-b3f2-4e8c-b563-e8acd0adef10

Q38825497-849ADDB4-DDBC-4F76-A5D4-31ECB8B97E50

P356

Q38825497-DAE7F00B-DF12-4698-925B-0E53B6B6349A

P407

Q38825497-C65A7FBB-0FCA-408A-A0DC-3F7CF0A93DBE

P433

Q38825497-86672D49-84BC-4D9B-8DD6-11FDF42C52E3

P478

Q38825497-73A7B51C-3797-453D-8B8B-681FE3550000

P50

Q38825497-21324E57-7E4D-4475-AA00-2E2D4374DF58

P577

Q38825497-67E97B66-5E8D-4FD9-8361-6024C9F459A9

P698

Q38825497-5117D711-0394-4A95-A518-850E747F3172

P921

Q38825497-4B9AFF42-B067-495B-866B-7B99767BE166

Q38825497-A06E7FB5-983B-4E14-A463-CD6E9333F719

Q38825497-F1FA92D1-0A90-42B4-AF54-A94BE4856F25

P356

P1433

Movement Disorders

P1476

Cerebrospinal fluid biomarkers ...... ysiology to clinical practice.

@en

P2093

Leonardo Biscetti

http://www.w3.org/2001/XMLSchema#string

Lucilla Parnetti

http://www.w3.org/2001/XMLSchema#string

Paolo Eusebi

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Molecular machines governing exocytosis of synaptic vesicles

Alpha-synuclein in Lewy bodies

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

P304

836-847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26656

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27145480

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

cerebrospinal fluid